ArticlePloS one2013
New insight into Ki67 expression at the invasive front in breast cancer.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of reduced XRCC2 expression with lymph node metastasis in breast cancer tissues.Familial cancer · 2014Pooled it
- Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Patient outcomes and clinician perspectives following one year ofTranslational breast cancer research : a journal focusing on translational research in breast cancer · 2025Article
- Flow cytometric analysis for Ki67 assessment in formalin-fixed paraffin-embedded breast cancer tissue.BMC biology · 2024Article
- Senescent Tumor Cells Are Frequently Present at the Invasion Front: Implications for Improving Disease Control in Patients with Locally Advanced Prostate Cancer.Pathobiology : journal of immunopathology, molecular and cellular biology · 2023Article
- Histological and Immunohistochemical Characteristics for Hereditary Breast Cancer Risk in a Cohort of Brazilian Women.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022Article
- Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics.Nature reviews. Genetics · 2021Review
- PFKFB4 Overexpression Facilitates Proliferation by Promoting the G1/S Transition and Is Associated with a Poor Prognosis in Triple-Negative Breast Cancer.Disease markers · 2021Article
- Article
- Quantitative assessment of Ki67 expression in correlation with various breast cancer characteristics and survival rate; cross sectional study.Annals of medicine and surgery (2012) · 2019Article
- Markers of Cancer Cell Invasion: Are They Good Enough?Journal of clinical medicine · 2019Review
- Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor.The American journal of pathology · 2019Article
- Article
- Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer.Nature cell biology · 2018Article
- Tracking the tumor invasion front using long-term fluidic tumoroid culture.Scientific reports · 2017Article
- Association of genetic polymorphisms in MIF with breast cancer risk in Chinese women.Clinical and experimental medicine · 2017Article
- Hormophysa triquerta polyphenol, an elixir that deters CXCR4- and COX2-dependent dissemination destiny of treatment-resistant pancreatic cancer cells.Oncotarget · 2017Article
- Quantum dot-based molecular imaging of cancer cell growth using a clone formation assay.Molecular medicine reports · 2016Article
- PBOV1 promotes prostate cancer proliferation by promoting G1/S transition.OncoTargets and therapy · 2016Article
- A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity.Nature · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the distribution of Ki67+ cells in breast cancer in relation to clinical-pathological parameters and prognosis. MATERIALS AND
methodsKi67 expression status was detected in 1,086 breast cancer specimens using immunohistochemistry staining and examining the relationship between the Ki67+ cells' location. Subsequently, clinical-pathological parameters and prognosis were determined.
resultsIn total, Ki67 protein expression was found in 781 (71.92%) of the 1,086 breast cancer specimens. Among the 781 Ki67+ cases, 461 were defined as diffuse type and 320 were defined as borderline type. After universal correlation analysis, significant differences were observed in age, histological grade, metastatic nodes, postoperative distant metastasis, and molecular subtype between Ki67+ and Ki67- cases (P = 0.01, 0.001, 0.001, 0.001, and 0.001, respectively). After subgroup analysis, the borderline cases were found to be characterized by a high distant metastasis rate compared to the diffuse cases as well as the Ki67- cases (P = 0.001). No differences were observed between diffuse type or Ki67- cases (P = 0.105). Multivariate analysis showed that age, tumor size, histological grade, lymph node metastasis, molecular subtype, and the Ki67 distribution pattern were observed to be related to postoperative distant metastasis (all P<0.05). Furthermore, borderline type was shown to attain a significantly more distant bone and liver metastasis and worse disease-specific survival than the other types (P = 0.001). In the Cox regression test, the Ki67 distribution pattern was detected as an independent prognostic factor (P = 0.001).
conclusionThe distribution pattern of Ki67 may be a new independent prognostic factor for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.